InterVenn Company

InterVenn unlocks the glycoproteome using artificial intelligence for the development of transformational healthcare solutions in DX and Rx.

Total Funding: $127.8M
Headquarters: South San Francisco, California, United States
Estimated Revenue: $50M to $100M
Last Funding Type: Venture - Series Unknown
Technology: Other
Investor Type: info@venn.bio
Investors Number: 7
Industry: Medical BioTech